Tomorrow, Tuesday, 6/18 - please join us for a webinar on one of the most fascinating fields in biotech! Still plenty of time to register...

This weekend at #AspenIdeasHealth, BioAge CEO Kristen Fortney joins Laura 🌲 ⛰️ of age1 and Richard Klausner of Altos Labs in a wide-ranging discussion of the science that is bringing us closer to extending human healthspan. Allison Aubrey will moderate! aspenideas.org/sessions/you-c…

At American Diabetes Association’s annual meeting, BioAge CMO Paul Rubin, MD shared data showing that in mice, addition of our lead drug azelaprag to an incretin regimen increases weight loss while improving body composition. Ph2 trial for obesity planned in mid-2024. businesswire.com/news/home/2024…

BioAge is proud to sponsor @longevitygl’s next “Longevity Dialogues.” Ashley Zehnder of @Faunabio and Nick Hertz of MontaraTx will share their perspectives on pharma partnerships in longevity biotech. Join us! Tuesday, June 25 • San Francisco Register! 👉🏼lu.ma/g57i0xir

Full video of the webinar is now available! Thanks to Hanadie, Alex, and Ben for a fascinating conversation about the many ways that AI can catalyze progress in longevity biotech.

Check out the full video of the #AspenIdeasHealth panel on extending human healthspan, featuring BioAge CEO Kristen Fortney, Laura 🌲 ⛰️ of age1, and Richard Klausner of Altos Labs in conversation with Allison Aubrey. Thanks to all for a fantastic discussion! youtube.com/watch?v=Elt4xG…

Next week at a HitGen webinar, BioAge SVP-Research Rusty Montgomery will describe how we used DNA-encoded libraries to discover novel inhibitors of NLRP3, which we are developing for diseases driven by neuroinflammation. 📅 6/17/24 2pm ET 👉🏼 Register: xtalks.com/webinars/evolv…

Starts at 11 AM PT / 2 PM ET today - still time to register!

The @bioagepodcast features the people & companies advancing the science of human longevity and discovering drugs to extend healthspan. Our newest episode just dropped!

Thanks to all who joined for our fourth Boston longevity biotech mixer! Deep gratitude to our speakers Ulrike Trendelenburg from Novartis DARe and Omar Abudayyeh + Jonathan Gootenberg from Harvard Medical School; our co-sponsors Hevolution Foundation; and our gracious hosts at Boston Consulting Group. Can’t wait for next time!

BioAge is pleased to announce the appointment of Jean-Pierre Garnier, PhD, as Chair of our Board of Directors. Dr. Garnier, who was CEO of GSK and board chair of multiple biopharma companies, brings unparalleled industry leadership to our Board. businesswire.com/news/home/2024…

BioAge is proud to sponsor the 2024 ARDD Meeting, the 11th in a series that has grown into the essential annual conference for the longevity biotech sector. Kicking off today in Copenhagen 🇩🇰 — looking forward to seeing all of our friends & colleagues who will be attending!

We are delighted to welcome Sangita Ghosh, PhD, as BioAge's Senior VP of CMC. With >20 years of experience in pharmaceutical development, she will be instrumental as we progress our lead candidate, azelaprag, through clinical trials.

At ARDD Meeting today, our VP-Data Science Naisha Shah gave a talk on target discovery for metabolic disease at the intersection of exercise & aging. She showcased how how we use human longevity data to identify exercise-induced pathways to develop drugs for metabolic diseases.

Action shot! Naisha Shah, BioAge's VP-Data Science, giving her talk entitled "Targeting aging biology: exercise induced pathways for the treatment of metabolic disease" on the main stage at the ARDD Meeting in Copenhagen.